Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving 3.27% from the previous trading session.

Future AI-guided genomic analysis offers the potential to further optimize gene constructs, expression profiles, and performance traits, accelerating the development of next-generation materials.

Cathie Wood's ARK bought $9.67M in Roblox stock Feb 9 while selling PagerDuty for fifth day. Full breakdown of ARK Invest ...

Cathie Wood’s Ark Invest expanded its Bullish holdings, buying additional shares as the stock surged more than 16% amid a ...

WUHC ’s annual event is the nation’s largest undergraduate healthcare conference. The day included four panels on topics of ...

Is On Investors’ Radar Today Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt ...

Cathie Wood’s ARK Invest continued trimming its exposure to Coinbase on Friday, selling roughly $22 million worth of shares across three exchange-traded ...

It's a potential game-changing technology. The company just needs to prove to the world that it works well enough.

The spotlight is now firmly on clinical validation for Exscientia following its merger with Recursion Pharmaceuticals. The company’s core artificial intelligenc ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report), Caribou Biosciences (CRBU – Research Report) and Boston Scien ...

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.9, denoting a -4.88% move from the preceding trading day.

The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...